Literature DB >> 19716166

Heparin and maternal fetal interface: why should it work to prevent pregnancy complications?

Nazli Hossain1, Frederick Schatz, Michael J Paidas.   

Abstract

Anticoagulant therapy has been used extensively for the prevention of recurrent pregnancy losses, and other placenta mediated complications, including prevention of preeclampsia and fetal growth restriction. While heparin anticoagulation is a standard treatment for antiphospholipid antibody syndrome, it is increasingly being used in the prevention of placenta mediated complications. In this article, we explore the role of heparin at maternal-fetal interface, the molecular mechanism of action for heparin, and ongoing basic and translational work being done to elucidate heparin's principal mechanisms of action.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19716166     DOI: 10.1016/j.thromres.2009.08.001

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  3 in total

1.  Silica and titanium dioxide nanoparticles cause pregnancy complications in mice.

Authors:  Kohei Yamashita; Yasuo Yoshioka; Kazuma Higashisaka; Kazuya Mimura; Yuki Morishita; Masatoshi Nozaki; Tokuyuki Yoshida; Toshinobu Ogura; Hiromi Nabeshi; Kazuya Nagano; Yasuhiro Abe; Haruhiko Kamada; Youko Monobe; Takayoshi Imazawa; Hisae Aoshima; Kiyoshi Shishido; Yuichi Kawai; Tadanori Mayumi; Shin-Ichi Tsunoda; Norio Itoh; Tomoaki Yoshikawa; Itaru Yanagihara; Shigeru Saito; Yasuo Tsutsumi
Journal:  Nat Nanotechnol       Date:  2011-04-03       Impact factor: 39.213

2.  The Role of Heparin in Embryo Implantation in Women with Recurrent Implantation Failure in the Cycles of Assisted Reproductive Techniques (Without History of Thrombophilia).

Authors:  Kobra Hamdi; Shahla Danaii; La'ya Farzadi; Sedigheh Abdollahi; Allahverdi Chalabizadeh; Somayae Abdollahi Sabet
Journal:  J Family Reprod Health       Date:  2015-06

Review 3.  Dysregulation of Complement Activation and Placental Dysfunction: A Potential Target to Treat Preeclampsia?

Authors:  E Pierik; Jelmer R Prins; Harry van Goor; Gustaaf A Dekker; Mohamed R Daha; Marc A J Seelen; Sicco A Scherjon
Journal:  Front Immunol       Date:  2020-01-15       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.